Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Completed · Phase 2

Conditions studied: Sickle Cell Disease

In brief

An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.

Key facts

Study ID
NCT05725902
Run by
Novo Nordisk A/S
People needed
12
Starts
2024-03-09
Expected to finish
2026-03-09
Last updated by the study team
2026-04-08

Who can join

Age: 12 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.